Zavegepant Chemical Properties

Boiling point:

933.7±65.0 °C(Predicted)

Density 

1.285±0.06 g/cm3(Predicted)

pka

11.68±0.70(Predicted)

form 

Solid

color 

White to off-white

InChIKey

JJVAPHYEOZSKJZ-JGCGQSQUSA-N

SMILES

N1(C(N[C@H](CC2C=C(C)C3=C(C=2)C=NN3)C(N2CCN(C3CCN(C)CC3)CC2)=O)=O)CCC(C2=CC3=C(NC2=O)C=CC=C3)CC1

Zavegepant Usage And Synthesis

Description

Zavegepant, also known as Vazegepant, BHV-3500 and BMS 742413, is a highly potent, selective and structurally unique small molecule CGRP receptor antagonist. Vazegepant is the first and only CGRP receptor antagonist for intranasal administration currently in development for the acute treatment of migraine.

Uses

Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology[1][2][3][4].

brand name

Zavzpret

Mechanism of action

Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine. The pathophysiology of migraine has not been fully elucidated; however, specific vasoactive substances and neurotransmitters such as CGRP, neurokinin A, nitric oxide, and substance P may participate in the neurovascular and cortical spreading depression mechanisms.

Side effects

Zavegepant is generally well tolerated with side effects of dysgeusia, nausea, vomiting, and nasal discomfort that are generally transient and mild-to-moderate in severity.

References

[1] Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020 Jun;33(3):309-315. DOI:10.1097/WCO.0000000000000806
[2] Gene M Dubowchik, et al. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. DOI:10.1021/acs.jmedchem.9b01810
[3] Capi M, De Angelis V, De Bernardini D, et al. Zavegepant[M]//Novel Synthetic Drugs in Migraine. Cham: Springer International Publishing, 2022: 67-72.
[4] Jéssica Barreto Ribeiro Dos Santos, et al. Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Eur J Pharmacol.2022 May 5:922:174902. DOI:10.1016/j.ejphar.2022.174902